Share

Glaxo pays Aspen R761m to end collaboration

Cape Town - Aspen Global's local arm Aspen Pharmacare [JSE:APN] announced on Tuesday that GlaxoSmithKline (GSK) paid the JSE-listed company £45m (R761.07m) to end its sub-Saharan Africa (SSA) collaboration.

The payment officially ended the collaboration between the two pharmaceutical companies, after it announced on September 12 2016 that GSK would end its collaboration.

“Pharmacare and GSK had agreed to cancel the rights of Pharmacare to collaborate in the sub-Saharan business of GSK and that GSK would pay Pharmacare £45m as consideration for the cancellation of the SSA collaboration,” Pharmacare said in a statement on Tuesday.

The announcement of the end of the collaboration was followed by the September 29 2016 announcement that GSK would dispose all its shares in Aspen, worth about R8.47bn. 

Aspen said in a statement at the time that the disposal would in no way affect the ongoing collaboration between Aspen and GSK in South Africa and a number of other trading relationships between the two companies.

However, shares slumped to their lowest in four months at the time.

Aspen CEO Stephen Saad said on September 29 that “Aspen’s exceptional relationship with GSK and the many mutually beneficial trading activities between the companies remain unaffected by this disposal”.

“We are pleased that Aspen shareholders are relieved of the uncertainty caused by GSK’s stated intention to dispose of its interests, which eliminates the overhang caused by this uncertainty,” he said.

Aspen’s share price shifted slightly higher by 0.37% to R284.63 by 10:00 on Tuesday, with a price/earnings ratio of 31.85. The share price has declined 34% since it traded at R380.36 on 31 July 2016 and 54% since it traded at R438 on 1 February 2015.

Aspen Global also announced on Tuesday that it had exercised its option to acquire Fraxiparine and Arixtra in certain countries to which GSK retained the rights, most notably China, for a consideration of £45m.

Both transactions were completed on December 31.

Read Fin24's top stories trending on Twitter:

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Rand - Dollar
19.14
-0.1%
Rand - Pound
23.78
+0.0%
Rand - Euro
20.45
+0.0%
Rand - Aus dollar
12.45
-0.4%
Rand - Yen
0.12
-0.0%
Platinum
926.80
+0.7%
Palladium
1,026.50
+0.1%
Gold
2,322.83
+0.0%
Silver
27.37
+0.2%
Brent Crude
88.42
+1.6%
Top 40
68,520
+0.7%
All Share
74,494
+0.7%
Resource 10
60,134
+0.9%
Industrial 25
103,756
+0.9%
Financial 15
15,920
+0.2%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders